Vendor Intelligence Report: Cyco peptide Bio CPB

Published 3 Jul 2026. 18-page investigative report on who is behind Cyco peptide Bio CPB: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Cyco peptide Bio CPB is a narrow but high-friction case: a research-peptide vendor listing China as its location, whose public storefront was offline during inspection while the domain continued to show fresh TLS-certificate activity. The recoverable footprint is short and thin: a 2025 one-year domain, Shandong registrant province, zero Wayback snapshots, no verified legal entity, no named personnel, and no official batch-authentication channel.

Across 6 Finnrick lab tests the overall pass rate is 50% (3 pass / 3 fail). All Finnrick data concerns retatrutide, so the buyer signal is product-specific rather than catalog-wide. Identity confirmation is the more favorable part of the file; the weak point is fill accuracy and traceability, with the same short run containing a strong batch-identified certificate and a severe underdose certificate without useful lot control. Ratings weaken under stricter grading, underscoring that purity is not the same as label accuracy.

The site posture is not simple abandonment. Direct inspection found an HTTP 404, but certificate-transparency logs show continued maintenance, including a fresh Google Trust Services certificate immediately before the July field run. Infrastructure pivots connect CPB through shared waimaoidc.com mail service to a grey-market tobacco storefront displaying fabricated placeholder contact details and to another offline domain. That does not prove common ownership, but it changes how a buyer should think about authentication, COA linkage, and payment-channel risk.

Inside the full report:

  • Appendix A Finnrick laboratory data for CPB retatrutide, plus methodology-divergence and trajectory charts
  • Dated evidence timeline for domain registration, storefront outages, TLS issuance, and lab events
  • RDAP, DNS, Cloudflare, MX, SPF, and certificate-transparency analysis of cycopeptidebio.com
  • Infrastructure-pivot comparison of cycopeptidebio.com, tobaccolifes.com, and luckymonkey.sale
  • Corporate-identity, archive, Trustpilot, LinkedIn, Reddit, forum, and affiliate-promotion dead-end log
  • Material buyer-risk matrix focused on retatrutide dose accuracy, traceability, and channel authentication

Risk assessment

  • Retatrutide quantity-accuracy risk — high: Retatrutide is the only tested product; 6 Finnrick tests show 3 pass / 3 fail, 71.85% rating, including a 20 mg vial at 7.4 mg (-63.0%).
  • Retatrutide batch-traceability risk — high: Four of six retatrutide samples lacked batch IDs, blocking reliable COA linkage, recall review, complaint handling, or adverse-event investigation.
  • Anonymous/offline storefront and authentication risk — high: The one-year 2025-09-09 domain is publicly 404, has no verified legal entity or named personnel, and offers no official channel list, batch lookup, or anti-counterfeit mechanism.
  • Shared gray-market storefront infrastructure concern — medium: cycopeptidebio.com shares mx.waimaoidc.com infrastructure with tobaccolifes.com and luckymonkey.sale; tobaccolifes.com displayed fabricated placeholder contact details.
  • Market-validation opacity risk — medium: No organic mentions, independent reviews, Trustpilot profile, LinkedIn personnel, Reddit discussion, peptide-forum discussion, or X/web affiliate footprint was found in the covered searches.